

1 **Balloon Angioplasty as the First-Choice Treatment for Intracranial Atherosclerosis-**
2 **Related Emergent Large Vessel Occlusion Involving the Microcatheter “First-Pass Effect”**

3

4 Liang Zhang, MM^{1#}, Xiongjun He, MD^{2#}, Kaifeng Li, MM², Li Ling, MD², Min Peng, MM¹,
5 Li'an Huang, MD^{1*}, Yajie Liu, MD^{2*}

6

7 ¹Department of Neurology, First Affiliated Hospital of Jinan University, Guangzhou, China

8 ²Department of Neurology, Shenzhen Hospital of Southern Medical University, Shenzhen, China

9 #Contributed equally.

10

11 ***Correspondence:**

12 Yajie Liu, MD, Department of Neurology, Shenzhen Hospital of Southern Medical University,
13 NO 1333 Xiniu Rd, Baoan Dt, Shenzhen 518101, China. Email: docliu18@qq.com

14 Li'an Huang, MD, Department of Neurology, First Affiliated Hospital of Jinan University, NO
15 613 West Huangpu Rd, Tianhe Dt, Guangzhou 510630, China. Email: huanglian1306@126.com

16

17 **ABSTRACT**

18 **Background:** It is unknown whether balloon angioplasty can be a first-choice treatment for
19 intracranial atherosclerosis-related emergent large vessel occlusion (ICAS-ELVO) with small
20 clot burden. The microcatheter “first-pass effect” is a valid predictor of ICAS-ELVO with small
21 clot.

22 **Objective:** To determine balloon angioplasty’s efficacy as first-choice treatment for ICAS-ELVO
23 involving the microcatheter “first-pass effect” during endovascular treatment (EVT).

24 **Methods:** This continuous retrospective analysis assessed ICAS-ELVO patients presenting with
25 the microcatheter “first-pass effect” during EVT. Patients were divided into two first-choice
26 treatment-based groups: preferred balloon angioplasty (PBA) and preferred mechanical
27 thrombectomy (PMT). Efficacy and safety outcomes were compared between groups.

28 **Results:** Seventy-six patients with ICAS-ELVO involving the microcatheter “first-pass effect”
29 during EVT were enrolled. Compared with patients in PMT group, patients in PBA group were
30 associated with (i) a higher rate of first-pass recanalization (54.0% vs. 28.9%, $p=.010$) and
31 complete reperfusion (expanded thrombolysis in cerebral ischemia $\geq 2c$; 76.0% vs. 53.8%,
32 $p=.049$), (ii) a shorter puncture-to-recanalization time (49.5 min vs. 56.0 min, $p<.001$), (iii) less
33 operation costs (48,499.5¥ vs. 99,086.0¥, $p<.001$), and (iv) more excellent functional outcomes
34 (modified Rankin scale:0-1; 44.0% vs. 19.2%, $p=.032$) at 90 days. No significant differences in
35 symptomatic intracranial hemorrhage (12.0% vs. 15.4%, $p>.999$) and mortality (10.0% vs. 7.7%,
36 $p>.999$) were noted. Logistic regression analysis revealed that first-choice treatment was an
37 independent predictor of 90-day excellent functional outcomes (adjusted odds ratio [aOR] =0.10,
38 95% CI: 0.02–0.66, $p=.017$).

39 **Conclusion:** Balloon angioplasty, as the first-choice treatment, potentially improves 90-day
40 functional outcomes for ICAS-ELVO patients with microcatheter “first-pass effect” during
41 EVT.

42 **What is already known on this topic :** Compared with large vessel occlusion caused by
43 embolization, mechanical thrombectomy has lower recanalization rate, longer procedure time,
44 and poorer prognosis for patients with intracranial atherosclerosis-related emergent large vessel
45 occlusion(ICAS-ELVO).

46 **What this study adds** : This study revealed that balloon angioplasty, as the first-choice
47 treatment, potentially improves 90-day outcomes, shortens procedure time, and reduces
48 operation costs for patients with ICAS-ELVO involving the microcatheter “first-pass effect”
49 during endovascular treatment.

50 **How this study might affect research, practice or policy** : We believe that our study makes a
51 significant contribution to the literature because its findings suggest that rapid and accurate
52 methods of diagnosing the etiology and clot burden of ELVO as well as the development of an
53 individualized EVT strategy based on etiology and clot burden need to be established.

54 **Keywords:** balloon angioplasty; clot burden; endovascular treatment; intracranial
55 atherosclerosis; mechanical thrombectomy

56 **Abbreviations:** aOR, adjusted odds ratio; CI, confidence interval; CT, computed tomography;
57 ELVO, emergent large vessel occlusion; eTICI, expanded thrombolysis in cerebral ischemia;
58 EVT, endovascular treatment; FPR, first pass recanalization; ICAS, intracranial atherosclerosis;
59 IQR, interquartile range; mRS, modified Rankin Scale; MT, mechanical thrombectomy; NIHSS,
60 National Institutes of Health Stroke Scale; PBA, preferred balloon angioplasty; PMT, preferred
61 mechanical thrombectomy; PRT, puncture to recanalization time; SD, standard deviation; t-PA,
62 tissue-type plasminogen activator; sICH, symptomatic intracranial hemorrhage.

63

64 **INTRODUCTION**

65 Mechanical thrombectomy (MT) has been the gold-standard of reperfusion therapy for patients
66 with emergent large vessel occlusion (ELVO); however, these studies’ participants
67 predominantly originated from Western populations, and the primary etiology of vascular

68 occlusion was embolism¹⁻⁵. When treating intracranial atherosclerosis-related emergent large
69 vessel occlusion (ICAS-ELVO), MT results in a lower recanalization rate, longer procedure
70 times, and poorer outcomes than when treating embolism-induced vessel occlusion, and a
71 significant number of patients require rescue therapy⁶⁻⁹. Patients with ICAS-ELVO encounter
72 unique technical challenges during endovascular recanalization therapy.

73 ICAS-ELVO is related to in-situ atherothrombotic occlusion and usually has a smaller clot
74 burden¹⁰, for which MT is often inefficient. Moreover, additional and repeated MT tends to
75 damage the vascular endothelium and increases the risk of reocclusion. Balloon angioplasty has
76 proven safe in ICAS-ELVO rescue therapy following MT, and we speculate that it may be a
77 better first-choice treatment than MT for ICAS-ELVO in patients with a small clot burden.

78 Though certain studies have demonstrated the feasibility of direct angioplasty for patients with
79 ICAS-ELVO¹¹⁻¹⁴, these studies did not define the clot burden of the included patients. The
80 microcatheter “first-pass effect” is considered a valid predictor of ICAS-ELVO¹⁵, and it often
81 suggests an occluded vessel with a small clot burden. Thus, we conducted this retrospective
82 study to determine whether balloon angioplasty could be the first-choice treatment for ICAS-
83 ELVO in patients with small clot burden, which was defined through the microcatheter “first-
84 pass effect” that presented during endovascular treatment (EVT).

85

86 **METHODS**

87 **Patients**

88 We reviewed the information of the consecutively collected ELVO patients who underwent
89 EVT between October 2018 and December 2021 in Shenzhen Hospital of Southern Medical
90 University. We enrolled patients who:(i) were aged >18 years, (ii) presented with isolated

91 intracranial internal carotid artery (ICA), M1 of middle cerebral artery, intracranial vertebral
92 artery or basilar artery occlusion , and (iii) the microcatheter “first-pass effect” was evaluated
93 before EVT . Patients were divided into two first-choice treatment-based groups: preferred
94 balloon angioplasty (PBA) and preferred mechanical thrombectomy (PMT). A flowchart of the
95 selection process is shown in **Figure 1**.
96 The etiologies of vessel occlusion and the microcatheter “first-pass effect” were assessed by two
97 neurointerventionalists using clinical and imaging data. The definition of the microcatheter
98 “first-pass effect” has been described in a previous study ¹⁵, and microcatheters used in this study
99 mainly were the XT-27[®] (Stryker Inc, Kalamazoo, MI, USA) and Rebar-27[®] (Medtronic Inc,
100 Minneapolis, MN, USA). Illustrative cases of the microcatheter “first-pass effect” are shown in
101 **Figure 2**. The basis for determining ICAS-ELVO included: (i) clear evidence of ICAS as the
102 culprit occluded vessel prior to this ischemic event; (ii) procedural evidence of ICAS after the
103 first pass of the microcatheter or balloon dilation/stent deployment; and (iii) significant fixed
104 focal stenosis (stenotic degree $\geq 50\%$) at the occlusion site. To reduce bias, both
105 neurointerventionists were tested in 10 selected cases of ELVO whose etiology was identified as
106 ICAS, and the diagnostic accuracy was 100%. This study was approved by our local medical
107 ethics committee.

108 **Endovascular Treatment**

109 Our center is a national senior stroke center and has extensive experience in EVT. Patients with
110 intravenous thrombolytic indications were administered t-PA intravenous thrombolytic therapy,
111 and EVT was performed in patients with intravascular indications after they had provided written
112 informed consent. Decisions regarding recanalization strategies were based on the
113 neurointerventionalists’ discretion. When the first-choice treatment failed to recanalize or

114 maintain vascular patency, rescue therapy was performed at the appropriate time. The choice of
115 balloon size depended on the diameter measured at the proximal segment of the occluded vessel,
116 and the selected balloon size was generally smaller than the vessel's actual measured diameter.
117 The balloon was gradually pressurized using a pressure pump, and the maximum pressure did
118 not exceed the balloon's pressure. Patients with inadequate preparation for oral antiplatelet
119 agents received tirofiban before balloon angioplasty and/or stenting. All operations were
120 performed by neurointerventionalists who had > 5 years' EVT experience.

121 **Clinical Characteristics and Outcome Assessment**

122 The demographic, clinical, and imaging data of patients were collected from database of the
123 hospital. A head computed tomography (CT) scan was performed within 24 h after surgery to
124 determine the presence of intracranial hemorrhage. Head CT scans were reviewed at any time in
125 patients with early neurological deterioration.

126 The primary efficacy outcome was a postoperative 90-day excellent functional outcome
127 (modified Rankin scale [mRS: 0–1]), which was evaluated at 90 days follow-up reexamination
128 by neurologists who were not involved in the procedure, and telephone-based follow-up was
129 conducted if the patient could not return to the hospital. Secondary efficacy outcomes included
130 90-day functional independence (mRS 0–2), first-pass recanalization (FPR) rate, successful
131 recanalization rate and complete reperfusion rate. FPR is defined as a single thrombectomy, or
132 balloon angioplasty performed to achieve successful recanalization without the use of rescue
133 therapy. Successful recanalization was defined as grade 2b–3 expanded thrombolysis in cerebral
134 ischemia (eTICI), and complete reperfusion was defined as grade 2c–3 eTICI^{16 17}. The safety
135 endpoints were symptomatic intracranial hemorrhage and mortality within 24 h and 90 days after
136 surgery, respectively. Intracranial hemorrhage was assessed using CT, and symptomatic

137 intracranial hemorrhage was defined as neurological deterioration and a ≥ 4 -point increase in the
138 National Institutes of Health Stroke Scale score on admission (i-NIHSS) ¹⁸.

139 **Statistical Analysis**

140 SPSS 20.0 software (IBM Inc, Armonk, NY, USA) was used for statistical analysis. Categorical
141 variables are presented as frequencies (%) and non-normally distributed continuous variables as
142 medians (interquartile ranges [IQRs]). Between-group differences in clinical and procedural
143 characteristics were compared using the χ^2 -test, Student's t-test, Fisher's exact test, or Mann-
144 Whitney U depending on the type of variables analyzed. To evaluate independent predictors of
145 excellent functional outcome at 90 days, we performed a logistic regression model with the
146 following terms in the model: first-choice treatment, i-NIHSS, age, sex, and any other baseline
147 characteristic with a probability value ≤ 0.10 in univariate analyses. All tests were two-tailed,
148 and statistical significance was set at $p \leq 0.05$.

149 **RESULTS**

150 **Baseline Characteristics and Procedural Details**

151 A total of 76 patients were included in the study. Regarding the preferred treatment, 50 patients
152 underwent balloon angioplasty (PBA group), and 26 underwent MT (PMT group). In the PBA
153 group, 46.0% (23/50) patients underwent stenting and/or thrombectomy (13 patients underwent
154 stenting only, five underwent thrombectomy only, and five underwent both stenting and
155 thrombectomy). In the PMT group, 76.9% (20/26) patients underwent balloon angioplasty and/or
156 stenting (four patients underwent balloon angioplasty only, one underwent stenting only, and 15
157 underwent both balloon angioplasty and stenting).

158 Baseline characteristics and procedural details are summarized in Table 1. No significant
159 differences were noted in age, sex, hypertension, diabetes, hyperlipidemia, coronary artery

160 disease, smoking, history of stroke, i-NIHSS, intravenous thrombolysis, glycoprotein IIb/IIIa
 161 inhibitor use, general anesthesia, location of vessel occlusion, and time from puncture to first
 162 recanalization between the two groups. However, the time from puncture to recanalization (49.5
 163 min vs. 56.0 min, $p < .001$), rescue therapy rate (46.0% vs. 76.9%, $p = .010$), and operation costs
 164 (48,499.5 ¥ vs. 99,086.0 ¥, $p < .001$) were significantly lower in the PBA group than in the PMT
 165 group.

166 **Table 1** Comparison of baseline characteristics and procedural details between the two groups

	Overall (n=76)	PBA group (n=50)	PMT group (n=26)	P value
Age (y), mean (\pm SD)	64.9 \pm 10.7	64.6 \pm 10.7	65.7 \pm 10.8	0.660
Male, n (%)	58 (76.3)	39 (78.0)	19 (73.1)	0.632
Hypertension, n (%)	59 (77.6)	41 (82.0)	18 (69.2)	0.205
Diabetes mellitus, n (%)	33 (43.4)	20 (40.0)	13 (50.0)	0.404
Hyperlipidemia, n (%)	30 (39.5)	18 (36.0)	12 (46.2)	0.390
Coronary artery disease, n (%)	9 (11.8)	6 (12.0)	3 (11.5)	0.633
Smoking, n (%)	20 (26.3)	16 (32.0)	4 (15.4)	0.171
History of stroke, n (%)	21 (27.6)	15 (30.0)	6 (23.1)	0.522
Location of occlusion site, n (%)				0.532
Anterior circulation	49 (64.5)	31 (62.0)	18 (69.2)	
Posterior circulation	27 (35.5)	19 (38.0)	8 (30.8)	
i-NIHSS, median (IQR)	10 (8-13)	10 (8-13)	10 (8-14)	0.930
IV-tPA, n (%)	47 (61.8)	30 (60.0)	17 (65.4)	0.647

Glycoprotein IIb/IIIa inhibitor use, n (%)	54 (71.1)	35 (70.0)	19 (73.1)	0.779
General anesthesia, n (%)	38 (50.0)	26 (52.0)	12 (46.2)	0.629
Means of recanalization, n (%)				
Stent retrieval	30 (39.5)	7 (14.0)	23 (88.5)	<0.001**
Aspiration	7 (9.2)	3 (6.0)	4 (15.4)	0.222
Balloon dilation	69 (90.8)	50 (100.0)	19 (73.1)	<0.001**
Stenting	34 (44.7)	18 (36.0)	16 (61.5)	0.034**
Puncture-to-first recanalization time (min), median (IQR)	35.0 (29-42.5)	34.5 (27.0-41.0)	38.5 (33.0-45.0)	0.074
Puncture-to-recanalization time (min), median (IQR)	56.0 (34.5-85.5)	49.5 (31.0-70.0)	89.0 (70.0-110.0)	<0.001**
Rescue therapy, n (%)	43.0 (56.6)	23 (46.0)	20 (76.9)	0.010**
Costs (¥), median (IQR)	70,069.5 (44,593.5-95,210.0)	48,449.5 (42,749.0-77,478.0)	99,086.0 (67,639.0-113,486.0)	<0.001**

167 SD, standard deviation; i-NIHSS, National Institute of Health Stroke Scale score at admission;

168 IQR, interquartile range; IV-tPA, intravenous tissue-type plasminogen activator; ** $p \leq 0.05$.

169 **Recanalization and Clinical Outcome**

170 Safety and efficacy endpoint comparisons between the two groups are shown in Table 2. Overall,

171 98.7% (75/76) patients had grade 2b–3 eTICI, and one patient in the PMT group failed to

172 recanalize because of iatrogenic dissection. 65.8% (50/76) patients achieved 90-day functional

173 independence ($mRS \leq 2$), and 35.5% (27/76) patients achieved 90-day excellent functional

174 outcome (mRS \leq 1). The comparison of 90-day mRS score changes between the groups is shown
 175 in **Supplementary Figure 1**. No significant differences were observed in the successful
 176 revascularization rate (100% vs. 96.2%, p=.342), 90-day functional independence (72.0% vs.
 177 53.8%, p=.551), symptomatic intracranial hemorrhage rate (12.0% vs. 15.4%, p>.999), and
 178 mortality rate (10.0% vs. 7.7%, p>.999) between the two groups. However, the rates of FPR
 179 (54.0% vs. 28.9%, p=.010), complete reperfusion (76.0% vs. 53.8%, p=.049), and 90-day
 180 excellent functional outcomes (44.0% vs. 19.2%, p=.032) were significantly higher in the PBA
 181 group than in the PMT group.

182

183 **Table 2** Efficacy and safety endpoint comparisons between the two groups

	Overall (n=76)	PBA group (n=50)	PMT group (n=26)	P value
FPR, n (%)	33 (43.4)	27 (54.0)	6 (28.9)	0.010**
eTICI, n (%)				
\geq 2b (2b,2c,3)	75 (98.7)	50 (100.0)	25 (96.2)	0.342
\geq 2c (2c,3)	52 (68.4)	38 (76.0)	14 (53.8)	0.049**
90-d mRS, n (%)				
0-1	27 (35.5)	22 (44.0)	5 (19.2)	0.032**
0-2	50 (65.8)	36 (72.0)	14 (53.8)	0.551
sICH, n (%)	10 (13.2)	6 (12.0)	4 (15.4)	>0.999
Mortality, n (%)	7 (9.2)	5 (10.0)	2 (7.7)	>0.999

184 FPR, first-pass recanalization; eTICI, expanded thrombolysis in cerebral ischemia; mRS,

185 modified Rankin Scale; sICH, symptomatic intracranial hemorrhage; ** p \leq 0.05.

186
 187 Multivariate logistic regression analysis revealed that the i-NIHSS and first-choice treatment
 188 (PMT vs. PBA) were independent factors for 90-day excellent functional outcomes (adjusted
 189 odds ratio [aOR]=.53, 95% confidence interval [CI]: .36–.76, $p < 0.001$ and aOR=0.10, 95% CI:
 190 0.02–0.66, $p = .017$, respectively). The results of the univariate and multivariate logistic
 191 regression analyses are shown in Supplementary Table 1.

192
 193 **Supplementary Table 1** Logistic regression analysis for predicting 90-day excellent functional
 194 outcome ($mRS \leq 1$)

Variable	Univariate analysis		Multivariate analysis	
	OR (95% CI)	P value	aOR (95% CI)	P value
Age	0.96 (0.92–1.01)	0.097*	0.94 (0.88-1.01)	0.081*
Sex (Female vs. Male)	2.22 (0.76-6.53)	0.147	4.34 (0.74-25.44)	0.104
Vascular risk factors				
Hypertension	2.08 (0.60-7.15)	0.247
Diabetes mellitus	0.52 (0.20-1.38)	0.191
Hyperlipidemia	1.09 (0.42-2.83)	0.867
Coronary artery disease	1.53 (0.37-6.26)	0.554
Smoking	0.52 (0.16-1.62)	0.256
History of stroke	0.88 (0.30-2.53)	0.805
Location of occlusion site	0.51 (0.18-1.43)	0.198
i-NIHSS	0.59 (0.45–0.78)	<0.001**	0.53 (0.36-0.76)	<0.001**
IV-tPA	0.66 (0.25–1.74)	0.403
Glycoprotein IIb/IIIa use	0.42 (0.15-1.17)	0.096*	0.67 (0.15-3.02)	0.601
General anesthesia	0.44 (0.17-1.16)	0.096*	0.49 (0.12-1.99)	0.319
Means of recanalization				

Stent retrieval	0.85 (0.32-2.24)	0.747
Aspiration	NA	>0.999
Balloon dilation	0.71 (0.15-3.44)	0.672
Stenting	0.21 (0.07–0.62)	0.005**	0.33 (0.07-1.51)	0.152
First-choice treatment (PMT vs. PBA)	0.30 (0.10–0.93)	0.037**	0.10 (0.02-0.66)	0.017**

195 OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; i-NIHSS, National Institute of
 196 Health Stroke Scale score at admission; IV-tPA, intravenous tissue-type plasminogen activator;
 197 PBA, preferred balloon angioplasty; PMT, preferred mechanical thrombectomy; * $p \leq 0.10$; **
 198 $p \leq 0.05$.

199

200 DISCUSSION

201 For patients with ICAS-ELVO involving the microcatheter “first-pass effect” during EVT, two
 202 preferred treatments—MT and balloon angioplasty—were used for recanalization in this study.
 203 Our results indicate that the two treatments were comparable in terms of safety. However, they
 204 also show that balloon angioplasty, as the first-choice treatment, potentially increases the FPR
 205 and complete reperfusion rates, shortens the puncture-to-recanalization time, reduces the rescue
 206 therapy rate, and improves patients’ 90-day outcomes.
 207 MT is often accompanied by a lower recanalization rate, longer operation time, and a higher risk
 208 of vascular reocclusion in patients with ICAS-ELVO, a phenomenon that has always challenged
 209 neurointerventionalists. Owing to the special pathophysiological characteristics of ICAS-ELVO,
 210 researchers are attempting to develop a targeted EVT strategy based on etiological diagnosis.
 211 Certain studies have reported the advantages of direct angioplasty as a primary treatment for
 212 ICAS-ELVO, including shortening the procedure time and reducing the number of procedure

213 device attempts, with similar safety to that of MT^{13 14}. However, these studies did not define the
214 clot burden of the included patients, thus potentially affecting the persuasiveness of the results.
215 ICAS-ELVO is related to in situ thrombotic occlusion, which results from unstable plaque
216 ruptures and typically has a smaller clot burden; however, it is not absolute. Studies have
217 demonstrated that clot burdens are associated with patient prognosis after EVT¹⁹, and balloon
218 angioplasty, as the first-choice treatment for ICAS-ELVO, is often ineffective in cases of large
219 clot burdens. Thus, considering the clot burden as one of the bases for developing an EVT
220 strategy for patients with ICAS-ELVO is recommended. Although the clot burden score^{20 21} has
221 been used to evaluate clot burdens, its extensive and accurate evaluation in clinical practice
222 remains challenging. The microcatheter “first-pass effect” is a valuable predictor of ICAS-ELVO
223 based on the condition’s small clot size and relative ease of disintegration; when the
224 microcatheter passes through the occlusive site, it pushes part of the fresh thrombus to the blood
225 vessel’s distal end. Thus, the microcatheter “first-pass effect” may also be an effective indicator
226 of a small clot burden and an important variable for planning the ICAS-ELVO EVT strategy.
227 Rapid and complete reperfusion after thrombectomy is a predictor of favorable outcomes in
228 ELVO stroke^{16 22}. However, in patients with ICAS-ELVO, vessels tend to reocclude after
229 recanalization due to post-MT endothelial injury, and repeated MT and/or angioplasty must be
230 performed, thus substantially delaying reperfusion. Moreover, despite achieving successful
231 vessel recanalization after MT, a considerable number of patients fail to achieve complete
232 reperfusion because of residual stenosis. In this study, we compared the rates of FPR, complete
233 reperfusion ($eTIC \geq 2c$), and 90-day excellent functional outcomes ($mRS \leq 1$) between PBA and
234 PMT patients with ICAS-ELVO involving the microcatheter “first-pass effect” during EVT. The
235 results revealed that balloon angioplasty, as the first-choice treatment, potentially increases the

236 FPR and complete reperfusion rates and shortens the puncture-to-recanalization time; moreover,
237 the puncture-to-recanalization time and FPR rate were significantly correlated with 90-day
238 excellent functional outcomes. Our study implies that, for patients with ICAS-ELVO, balloon
239 angioplasty that entails selecting an appropriate balloon size and dilatation pressure for
240 angioplasty may be less invasive to the vascular endothelium than MT, which is beneficial for
241 maintaining vascular stability after the first recanalization.

242 EVT is recognized as an effective method for ELVO and has been increasingly promoted
243 worldwide. However, cost is often an important consideration for families and patients when
244 deciding on EVT, especially for self-funded patients with ICAS-ELVO. Given the complexity of
245 MT for ICAS-ELVO, neurointerventionalists often tend to estimate relatively high surgical costs,
246 thus further increasing the concern of the patient's family. Previous studies have observed that
247 direct balloon angioplasty can reduce the number of procedure device attempts in patients with
248 ICAS-ELVO; however, its ability to alleviate surgical costs has not been discussed. Our results
249 indicate that balloon angioplasty, as the first-choice treatment, potentially reduces the use of
250 remedial measures, thus relieving the economic burden on patients with ICAS-ELVO.

251 Considering that approximately one-third of ischemic strokes in Asia are caused by ICAS,
252 ensuring the effectiveness of EVT while reducing the cost as much as possible will benefit a
253 greater number of patients.

254 Emergency balloon angioplasty's major cause for concern is its increased risk of reocclusion
255 without adequate antiplatelet therapy or cerebral hemorrhage when antiplatelet therapy is
256 administered within 24 h of intravenous thrombolysis. Tirofiban is a short-acting intravenous
257 antiplatelet drug widely used in percutaneous coronary intervention, and studies have proven that
258 the combined use of tirofiban during or before EVT is feasible in patients with ICAS-ELVO^{11 23-}

259 ²⁵. Furthermore, tirofiban may be an alternative therapy for patients with post-MT ICAS-ELVO
260 ²⁶. In this study, we found that balloon angioplasty, as the first-choice treatment, neither
261 increased tirofiban use nor amplified the risk of symptomatic intracranial hemorrhage. In
262 contrast, tirofiban use was more aggressively required in the PMT group owing to endothelial
263 injury caused by additional and repeat MT. Another cause for concern in balloon angioplasty is
264 the “snowplowing” effect: branch occlusion following angioplasty may cause secondary
265 ischemia in the injury site. However, because the territory supplied by the neighboring side
266 branches is often already infarcted following the complete occlusion of the trunk vessel, the risk
267 of secondary ischemic injury due to “snowplowing” is not as high as anticipated ⁸.
268 Planning a targeted EVT strategy based on etiological diagnosis is an attractive option; however,
269 predicting the etiology of vascular occlusion promptly and accurately before EVT remains
270 difficult. Currently, no widely accepted diagnostic criteria for distinguishing atherothrombotic
271 ELVO from others and potential preprocedural methods for identifying signs of atherosclerosis
272 are available. For example, patients repeatedly suffering from transient ischemic attack-related
273 symptoms on the ipsilateral side before acute ischemic stroke, combined with risk factors
274 associated with atherosclerosis, have exhibited lower NIHSS scores and favorable collateral
275 circulation upon admission, which leads to the suspicion of ICAS-ELVO ⁹. Imaging predictors,
276 such as a core infarction located in the watershed area, severe calcification at the site of
277 occlusion, severe and/or multifocal narrowing on angiography, “tapered” occlusion ²⁷, “truncal-
278 type” occlusion ²⁸, and the microcatheter “first-pass effect,” ¹⁵ all support ICAS as the most
279 likely etiology. In the future, more diagnostic methods that enable the rapid and accurate
280 diagnosis of vascular occlusion’s etiology and provide a basis for treatment decisions are
281 warranted.

282 **Limitations**

283 There were several limitations in this study. First, our findings should be cautiously interpreted,
284 as the study is characterized by a small sample size, single center, and retrospective nature;
285 therefore, further prospective, multicenter, large sample-sized studies are required. Second,
286 although a small clot burden is the prerequisite for the existence of microcatheter “first-pass
287 effect,” its specificity and sensitivity to predict small clot burden need to be further tested in
288 more studies.

289

290 **CONCLUSION**

291 Our study reveals that balloon angioplasty, as the first-choice treatment, is potentially beneficial
292 in improving the rate of 90-day excellent functional outcomes, shortening the procedure time,
293 and reducing surgical costs for patients with ICAS-ELVO involving the microcatheter “first-pass
294 effect” during EVT. In the future, the rapid and accurate diagnosis of the etiology and clot
295 burden of ELVO and development of an individualized EVT strategy based on etiology and clot
296 burden will be the focus of our subsequent research.

297

298 **Conflict of Interest:** None.

299

300 **Disclosure of Funding:** None.

301

302 **Acknowledgments:** We are grateful to the clinicians and staff at the Shenzhen Hospital of
303 Southern Medical University who contributed to the medical intervention and data collection for

304 this study. We would like to thank Editage (www.editage.cn) for English language editing and
305 Charlesworth (www.cwauthors.com.cn) for statistical review.

306

307

308 **Author Contributions:** L.Z. and X.H. analyzed and interpreted the data and drafted the
309 manuscript. Y.L. conceived and designed the research. M.P. and K.L. evaluated the image. L.L.
310 and L.H. made critical revisions of the manuscript. All authors read and approved the final
311 manuscript.

312

313 **Ethical Statement:** The studies involving human participants were reviewed and approved by
314 the Clinical Research Ethics Committee of Shenzhen Hospital of Southern Medical University.
315 The patients/participants provided written informed consent to participate in this study.

316

317 **Data Availability Statement:** The datasets used and/or analyzed during the current study are
318 available from the corresponding author on reasonable request.

319

320 REFERENCES

- 321 1. Berkhemer OA, Fransen PS, Beumer D, et al. A randomized trial of intraarterial treatment for
322 acute ischemic stroke. *N Engl J Med* 2015;372(1):11-20. doi: 10.1056/NEJMoa1411587
- 323 2. Campbell BC, Mitchell PJ, Kleinig TJ, et al. Endovascular therapy for ischemic stroke with
324 perfusion-imaging selection. *N Engl J Med* 2015;372(11):1009-18. doi:
325 10.1056/NEJMoa1414792 [published Online First: 2015/02/12]

- 326 3. Goyal M, Demchuk AM, Menon BK, et al. Randomized assessment of rapid endovascular
327 treatment of ischemic stroke. *N Engl J Med* 2015;372(11):1019-30. doi:
328 10.1056/NEJMoa1414905 [published Online First: 2015/02/12]
- 329 4. Saver JL, Goyal M, Bonafe A, et al. Stent-retriever thrombectomy after intravenous t-PA vs. t-
330 PA alone in stroke. *N Engl J Med* 2015;372(24):2285-95. doi: 10.1056/NEJMoa1415061
- 331 5. Jovin TG, Chamorro A, Cobo E, et al. Thrombectomy within 8 hours after symptom onset in
332 ischemic stroke. *N Engl J Med* 2015;372(24):2296-306. doi: 10.1056/NEJMoa1503780
- 333 6. Kim YW, Hong JM, Park DG, et al. Effect of intracranial atherosclerotic disease on
334 endovascular treatment for patients with acute vertebrobasilar occlusion. *AJNR Am J*
335 *Neuroradiol* 2016;37(11):2072-8. doi: 10.3174/ajnr. A4844 [published Online First: 2016/06/18]
- 336 7. Hwang YH, Kim YW, Kang DH, et al. Impact of target arterial residual stenosis on outcome
337 after endovascular revascularization. *Stroke* 2016;47(7):1805-7. doi:
338 10.1161/STROKEAHA.116.014694
- 339 8. Lee JS, Lee SJ, Hong JM, et al. Endovascular Treatment of Large Vessel Occlusion Strokes
340 Due to Intracranial Atherosclerotic Disease. *J Stroke* 2022;24(1):3-20. doi:
341 10.5853/jos.2021.01375 [published Online First: 2022/02/09]
- 342 9. Tsang ACO, Orru E, Klostranec JM, et al. Thrombectomy outcomes of intracranial
343 atherosclerosis-related occlusions. *Stroke* 2019;50(6):1460-6. doi:
344 10.1161/STROKEAHA.119.024889 [published Online First: 2019/05/16]
- 345 10. Kang DH, Yoon W. Current Opinion on Endovascular Therapy for Emergent Large Vessel
346 Occlusion Due to Underlying Intracranial Atherosclerotic Stenosis. *Korean J Radiol*
347 2019;20(5):739-48. doi: 10.3348/kjr.2018.0809 [published Online First: 2019/04/18]

- 348 11. Jia B, Feng L, Liebeskind DS, et al. Mechanical thrombectomy and rescue therapy for
349 intracranial large artery occlusion with underlying atherosclerosis. *J Neurointerv Surg*
350 2018;10(8):746-50. doi: 10.1136/neurintsurg-2017-013489 [published Online First: 2017/12/06]
- 351 12. Zhang J, Jia B, Pan Y, et al. A comparison between different endovascular treatment
352 strategies for acute large vessel occlusion due to intracranial artery atherosclerosis: data from
353 ANGEL-ACT Registry. *Neuroradiology* 2022;64(8):1627-38. doi: 10.1007/s00234-022-02933-w
354 [published Online First: 2022/03/30]
- 355 13. Ma G, Sun X, Tong X, et al. Safety and Efficacy of Direct Angioplasty in Acute Basilar
356 Artery Occlusion Due to Atherosclerosis. *Front Neurol* 2021; 12:651653. doi:
357 10.3389/fneur.2021.651653 [published Online First: 2021/08/06]
- 358 14. Luo Y, Huang J, Yang Y, et al. Effect of direct angioplasty therapy on acute middle cerebral
359 artery occlusion with good leptomeningeal collateral. *Clin Neurol Neurosurg* 2020; 190:105744.
360 doi: 10.1016/j.clineuro.2020.105744 [published Online First: 2020/02/28]
- 361 15. Yi TY, Chen WH, Wu YM, et al. Microcatheter "First-Pass Effect" Predicts Acute
362 Intracranial Artery Atherosclerotic Disease-Related Occlusion. *Neurosurgery* 2019;84(6):1296-
363 305. doi: 10.1093/neuros/nyy183 [published Online First: 2018/05/24]
- 364 16. McTaggart RA, Ospel JM, Psychogios MN, et al. Optimization of endovascular therapy in
365 the neuroangiography suite to achieve fast and complete (Expanded treatment in cerebral
366 ischemia 2c-3) reperfusion. *Stroke* 2020;51(7):1961-8. doi: 10.1161/STROKEAHA.119.026736
367 [published Online First: 2020/06/23]
- 368 17. Almekhlafi MA, Mishra S, Desai JA, et al. Not all "successful" angiographic reperfusion
369 patients are an equal validation of a modified TICI scoring system. *Interv Neuroradiol*
370 2014;20(1):21-7. doi: 10.15274/INR-2014-10004 [published Online First: 2014/02/22]

- 371 18. Saver JL, Jahan R, Levy EI, et al. Solitaire flow restoration device versus the Merci Retriever
372 in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority
373 trial. *Lancet* 2012;380(9849):1241-9. doi: 10.1016/S0140-6736(12)61384-1
- 374 19. Treurniet KM, Yoo AJ, Berkhemer OA, et al. Clot Burden Score on Baseline Computerized
375 Tomographic Angiography and Intra-Arterial Treatment Effect in Acute Ischemic Stroke. *Stroke*
376 2016;47(12):2972-78. doi: 10.1161/STROKEAHA.116.014565 [published Online First:
377 2016/11/09]
- 378 20. Derraz I, Bourcier R, Soudant M, et al. Does clot burden score on baseline T2*-MRI impact
379 clinical outcome in acute ischemic stroke treated with mechanical thrombectomy? *J Stroke*
380 2019;21(1):91-100. doi: 10.5853/jos.2018.01921 [published Online First: 2019/02/09]
- 381 21. Derraz I, Pou M, Labreuche J, et al. Clot burden score and collateral status and their impact
382 on functional outcome in acute ischemic stroke. *AJNR Am J Neuroradiol* 2021;42(1):42-8. doi:
383 10.3174/ajnr. A6865 [published Online First: 2020/11/14]
- 384 22. Nikoubashman O, Dekeyzer S, Riabikin A, et al. True first-pass effect. *Stroke*
385 2019;50(8):2140-6. doi: 10.1161/STROKEAHA.119.025148 [published Online First:
386 2019/06/21]
- 387 23. Yoon W, Kim SK, Park MS, et al. Endovascular treatment and the outcomes of
388 atherosclerotic intracranial stenosis in patients with hyperacute stroke. *Neurosurgery*
389 2015;76(6):680-6; discussion 86. doi: 10.1227/NEU.0000000000000694 [published Online First:
390 2015/05/20]
- 391 24. Kim YW, Sohn SI, Yoo J, et al. Local tirofiban infusion for remnant stenosis in large vessel
392 occlusion: tirofiban ASSIST study. *BMC Neurol* 2020;20(1):284. doi: 10.1186/s12883-020-
393 01864-4 [published Online First: 2020/07/22]

- 394 25. Investigators RBT, Qiu Z, Li F, et al. Effect of Intravenous Tirofiban vs Placebo Before
395 Endovascular Thrombectomy on Functional Outcomes in Large Vessel Occlusion Stroke: The
396 RESCUE BT Randomized Clinical Trial. JAMA 2022;328(6):543-53. doi:
397 10.1001/jama.2022.12584 [published Online First: 2022/08/10]
- 398 26. Kang DH, Yoon W, Kim SK, et al. Endovascular treatment for emergent large vessel
399 occlusion due to severe intracranial atherosclerotic stenosis. J Neurosurg 2018;1-8. doi:
400 10.3171/2018.1.JNS172350 [published Online First: 2018/06/23]
- 401 27. Liang W, Wang Y, Du Z, et al. Intraprocedural angiographic signs observed during
402 endovascular thrombectomy in patients with acute ischemic stroke: a systematic review.
403 Neurology 2021;96(23):1080-90. doi: 10.1212/WNL.00000000000012069 [published Online
404 First: 2021/04/25]
- 405 28. Baek JH, Kim BM. Angiographical Identification of Intracranial, Atherosclerosis-Related,
406 Large Vessel Occlusion in Endovascular Treatment. Front Neurol 2019; 10:298. doi:
407 10.3389/fneur.2019.00298 [published Online First: 2019/05/02]

408

409 **FIGURE LEGENDS**

410 **Figure 1.** Flow chart of patient screening in this study

411 **Figure 2.** Illustrative cases of the microcatheter “first-pass effect.” (1): A 51-year-old male
412 patient with hypertension and diabetes for 5 years presented with an acute onset of left body
413 weakness (iNIHSS score: 9) for 11 h. Angiography revealed occlusion at the M1 segment of the
414 right MCA and “taper sign” (A); Angiography exhibited adequate collateral, and retro-flow
415 reconstituted the distal portion of M1 (B); An XT-27 microcatheter and a microwire were
416 navigated through the occlusion area to the distal patent artery, and the microcatheter was

417 subsequently withdrawn to the occlusion's proximal side. Angiography demonstrated blood flow
418 through the vessel at the occlusion site, which was defined as the microcatheter "first-pass
419 effect" (C); Direct balloon angioplasty (gateway 2.0 × 9.0 mm) achieved an mTICI score of 3
420 (D). (2): A 65-year-old male patient with hypertension for 11 years presented with
421 unconsciousness (iNIHSS score: 15) for 4 h. Angiography demonstrated that the V5 segment of
422 the right dominant vertebral artery was occluded (E); Angiography revealed the microcatheter
423 "first-pass effect" (F); Direct balloon angioplasty (Sino 2.25 × 15.0 mm) achieved an mTICI
424 score of 2b with focal dissection (G); An enterprise stent (4 × 39 mm) was placed at the stenotic
425 site, and angiography revealed an mTICI score of 3 (H).

426 **Supplementary Figure 1.** Comparison of modified Rankin Scale (mRS) scores at 90 days
427 between the two groups

347 patients with acute ischemic stroke and endovascular reperfusion therapy were enrolled in study

243 excluded

- 194 were diagnosed as non-atherosclerotic large intracranial vessel occlusion
- 31 were extracranial vessel occlusion or combined with tandem occlusion
- 4 without consistent etiological diagnosis between two neuro-interventionists
- 14 patients' clinical /imaging data were incomplete or missing

104 patients met isolated intracranial atherosclerosis-related emergent large vessel occlusion (ICAS-ELVO)

28 excluded

- 5 patients received arterial thrombolysis only
- 23 patients without microcatheter "first-pass effect"

PBA group
(balloon angioplasty as the preferred treatment)
N=50

PMT group
(mechanical thrombectomy as the preferred treatment)
N=26

